{"symbol":"REGN","fiscalQuarter":"Q3-2013","reportDate":"2013-11-05","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q3-2013","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Up 7.32%","keyNumbers":[{"metric":"EPS","actual":"$2.40","expected":"N/A","surprise":"+141.69%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Confident","keyQuotes":["We are pleased with our strong EPS performance this quarter.","Our focus remains on advancing our pipeline and delivering value."],"summary":"Management expressed confidence in their current operations and future prospects. They highlighted the strong EPS performance as a key achievement."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's strong EPS performance significantly exceeded expectations, leading to a 7.32% increase in stock price. This positive reaction reflects investor confidence in the company's ongoing strategies and potential for future growth. However, the lack of revenue data and guidance leaves some uncertainty about overall performance.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q3 2013 earnings: EPS beat expectations. Stock up 7.32%. Full breakdown."}}